Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Finkelstein EA, Ruhm C, Kosa KM. Economic causes and consequences of obesity. Annu Rev Public Health. 2005;26:239-57.